Main	O
outcome	O
measure	O
Negative	B-PrimaryOutcome
conversion	I-PrimaryOutcome
of	I-PrimaryOutcome
severe	I-PrimaryOutcome
acute	I-PrimaryOutcome
respiratory	I-PrimaryOutcome
syndrome	I-PrimaryOutcome
coronavirus	I-PrimaryOutcome
2	I-PrimaryOutcome
by	B-TimeFrame
28	I-TimeFrame
days	I-TimeFrame
,	O
analysed	O
according	O
to	O
the	O
intention	O
to	O
treat	O
principle	O
.	O

Adverse	B-OtherOutcome
events	I-OtherOutcome
were	O
analysed	O
in	O
the	O
safety	O
population	O
in	O
which	O
hydroxychloroquine	O
recipients	O
were	O
participants	O
who	O
received	O
at	O
least	O
one	O
dose	O
of	O
hydroxychloroquine	O
and	O
hydroxychloroquine	O
non	O
-	O
recipients	O
were	O
those	O
managed	O
with	O
standard	O
of	O
care	O
alone	O
.	O

Outcome	O

The	O
primary	O
outcomes	O
for	O
this	O
trial	O
were	O
whether	O
patients	O
had	O
negative	B-PrimaryOutcome
conversion	I-PrimaryOutcome
of	I-PrimaryOutcome
SARS	I-PrimaryOutcome
-	I-PrimaryOutcome
CoV	I-PrimaryOutcome
-	I-PrimaryOutcome
2	I-PrimaryOutcome
by	B-TimeFrame
28	I-TimeFrame
days	I-TimeFrame
and	O
whether	O
patients	O
with	O
severe	O
covid	O
-	O
19	O
had	O
clinical	B-PrimaryOutcome
improvement	I-PrimaryOutcome
by	B-TimeFrame
28	I-TimeFrame
days	I-TimeFrame
.	O

However	O
,	O
as	O
the	O
trial	O
was	O
stopped	O
early	O
and	O
only	O
two	O
patients	O
with	O
severe	O
disease	O
were	O
enrolled	O
,	O
results	O
on	O
clinical	O
improvement	O
are	O
not	O
presented	O
.	O

We	O
defined	O
negative	O
conversion	O
of	O
SARS	O
-	O
CoV	O
-	O
2	O
as	O
two	B-OutcomeDefinition
consecutive	I-OutcomeDefinition
reports	I-OutcomeDefinition
of	I-OutcomeDefinition
a	I-OutcomeDefinition
negative	I-OutcomeDefinition
result	I-OutcomeDefinition
for	I-OutcomeDefinition
SARS	I-OutcomeDefinition
-	I-OutcomeDefinition
CoV	I-OutcomeDefinition
-	I-OutcomeDefinition
2	I-OutcomeDefinition
at	I-OutcomeDefinition
least	I-OutcomeDefinition
24	I-OutcomeDefinition
hours	I-OutcomeDefinition
apart	I-OutcomeDefinition
without	I-OutcomeDefinition
a	I-OutcomeDefinition
subsequent	I-OutcomeDefinition
report	I-OutcomeDefinition
of	I-OutcomeDefinition
a	I-OutcomeDefinition
positive	I-OutcomeDefinition
result	I-OutcomeDefinition
by	I-OutcomeDefinition
the	I-OutcomeDefinition
end	I-OutcomeDefinition
of	I-OutcomeDefinition
the	I-OutcomeDefinition
study	I-OutcomeDefinition
.	O

We	O
considered	O
the	O
date	O
of	O
the	O
first	O
negative	O
report	O
as	O
the	O
date	O
of	O
negative	O
conversion	O
.	O

In	O
the	O
original	O
protocol	O
,	O
the	O
primary	O
endpoint	O
was	O
prespecified	O
as	O
the	O
“	O
Negative	B-PrimaryOutcome
conversion	I-PrimaryOutcome
rate	I-PrimaryOutcome
by	B-TimeFrame
Day	I-TimeFrame
10	I-TimeFrame
”	O
(	O
approved	O
by	O
the	O
ethics	O
committee	O
on	O
6	O
February	O
2020	O
)	O
.	O

However	O
,	O
with	O
the	O
increasing	O
knowledge	O
of	O
covid	O
-	O
19	O
from	O
our	O
clinical	O
practice	O
,	O
we	O
realised	O
that	O
the	O
duration	O
of	O
SARS	O
-	O
CoV	O
-	O
2	O
in	O
respiratory	O
samples	O
of	O
many	O
patients	O
was	O
longer	O
than	O
10	O
days	O
,	O
recently	O
highlighted	O
by	O
a	O
detailed	O
virological	O
study	O
.	O
14	O
We	O
therefore	O
modified	O
our	O
primary	O
outcome	O
to	O
test	O
whether	O
patients	O
had	O
a	O
negative	B-PrimaryOutcome
conversion	I-PrimaryOutcome
of	I-PrimaryOutcome
SARS	I-PrimaryOutcome
-	I-PrimaryOutcome
CoV	I-PrimaryOutcome
-	I-PrimaryOutcome
2	I-PrimaryOutcome
by	B-TimeFrame
28	I-TimeFrame
days	I-TimeFrame
(	O
approved	O
by	O
the	O
ethics	O
committee	O
on	O
17	O
February	O
2020	O
)	O
.	O

Probability	B-SecondaryOutcome
of	I-SecondaryOutcome
negative	I-SecondaryOutcome
conversion	I-SecondaryOutcome
at	B-TimeFrame
day	I-TimeFrame
4	I-TimeFrame
,	I-TimeFrame
7	I-TimeFrame
,	I-TimeFrame
10	I-TimeFrame
,	I-TimeFrame
14	I-TimeFrame
,	I-TimeFrame
or	I-TimeFrame
21	I-TimeFrame
was	O
specified	O
as	O
a	O
secondary	O
outcome	O
in	O
the	O
protocol	O
,	O
but	O
this	O
does	O
not	O
appear	O
on	O
the	O
trial	O
registration	O
list	O
.	O

The	O
listed	O
secondary	O
outcome	O
in	O
the	O
trial	O
registration	O
was	O
adverse	B-SecondaryOutcome
events	I-SecondaryOutcome
coded	B-OutcomeDefinition
using	I-OutcomeDefinition
the	I-OutcomeDefinition
latest	I-OutcomeDefinition
version	I-OutcomeDefinition
of	I-OutcomeDefinition
Medical	I-OutcomeDefinition
Dictionary	I-OutcomeDefinition
for	I-OutcomeDefinition
Regulatory	I-OutcomeDefinition
Activities	I-OutcomeDefinition
coding	I-OutcomeDefinition
dictionary	I-OutcomeDefinition
,	I-OutcomeDefinition
recorded	I-OutcomeDefinition
in	I-OutcomeDefinition
standard	I-OutcomeDefinition
medical	I-OutcomeDefinition
terminology	I-OutcomeDefinition
and	I-OutcomeDefinition
graded	I-OutcomeDefinition
according	I-OutcomeDefinition
to	I-OutcomeDefinition
the	I-OutcomeDefinition
National	I-OutcomeDefinition
Cancer	I-OutcomeDefinition
Institute	I-OutcomeDefinition
Common	I-OutcomeDefinition
Terminology	I-OutcomeDefinition
Criteria	I-OutcomeDefinition
for	I-OutcomeDefinition
Adverse	I-OutcomeDefinition
Events	I-OutcomeDefinition
.	O

Other	O
prespecified	O
secondary	O
outcomes	O
not	O
listed	O
in	O
the	O
trial	O
registration	O
but	O
included	O
in	O
the	O
protocol	O
were	O
the	O
probabilities	B-SecondaryOutcome
of	I-SecondaryOutcome
alleviation	I-SecondaryOutcome
of	I-SecondaryOutcome
clinical	I-SecondaryOutcome
symptoms	I-SecondaryOutcome
;	O
improvement	B-SecondaryOutcome
of	I-SecondaryOutcome
C	I-SecondaryOutcome
reactive	I-SecondaryOutcome
protein	I-SecondaryOutcome
,	O
erythrocyte	B-SecondaryOutcome
sedimentation	I-SecondaryOutcome
rate	I-SecondaryOutcome
,	O
tumour	B-SecondaryOutcome
necrosis	I-SecondaryOutcome
factor	I-SecondaryOutcome
α	I-SecondaryOutcome
,	O
interleukin	B-SecondaryOutcome
6	I-SecondaryOutcome
,	O
and	O
absolute	B-SecondaryOutcome
blood	I-SecondaryOutcome
lymphocyte	I-SecondaryOutcome
count	I-SecondaryOutcome
;	O
improvement	B-SecondaryOutcome
of	I-SecondaryOutcome
lung	I-SecondaryOutcome
lesions	I-SecondaryOutcome
on	I-SecondaryOutcome
chest	I-SecondaryOutcome
radiology	I-SecondaryOutcome
;	O
all	B-SecondaryOutcome
cause	I-SecondaryOutcome
death	I-SecondaryOutcome
;	O
and	O
disease	B-SecondaryOutcome
progression	I-SecondaryOutcome
in	I-SecondaryOutcome
patients	I-SecondaryOutcome
with	I-SecondaryOutcome
mild	I-SecondaryOutcome
to	I-SecondaryOutcome
moderate	I-SecondaryOutcome
disease	I-SecondaryOutcome
.	O

The	O
time	O
frame	O
for	O
these	O
secondary	O
outcomes	O
was	O
from	B-TimeFrame
randomisation	I-TimeFrame
to	I-TimeFrame
28	I-TimeFrame
days	I-TimeFrame
.	O

Prespecified	O
secondary	O
outcomes	O
for	O
patients	O
with	O
severe	O
disease	O
are	O
not	O
listed	O
here	O
but	O
are	O
included	O
in	O
the	O
protocol	O
.	O

Owing	O
to	O
the	O
early	O
termination	O
of	O
our	O
study	O
,	O
we	O
could	O
not	O
justify	O
the	O
results	O
from	O
these	O
analyses	O
with	O
an	O
underpowered	O
sample	O
size	O
and	O
therefore	O
decided	O
not	O
to	O
emphasise	O
them	O
in	O
this	O
paper	O
to	O
avoid	O
misinterpretation	O
.	O

The	O
only	O
one	O
presented	O
here	O
is	O
the	O
alleviation	B-SecondaryOutcome
of	I-SecondaryOutcome
clinical	I-SecondaryOutcome
symptoms	I-SecondaryOutcome
within	B-TimeFrame
28	I-TimeFrame
days	I-TimeFrame
,	O
which	O
is	O
an	O
important	O
outcome	O
of	O
interest	O
prespecified	O
in	O
our	O
protocol	O
.	O

The	O
definition	O
of	O
the	O
alleviation	O
of	O
clinical	O
symptoms	O
was	O
resolving	B-OutcomeDefinition
from	I-OutcomeDefinition
fever	I-OutcomeDefinition
to	I-OutcomeDefinition
an	I-OutcomeDefinition
axillary	I-OutcomeDefinition
temperature	I-OutcomeDefinition
of	I-OutcomeDefinition
36	I-OutcomeDefinition
.	I-OutcomeDefinition
6	I-OutcomeDefinition
°	I-OutcomeDefinition
C	I-OutcomeDefinition
or	I-OutcomeDefinition
below	I-OutcomeDefinition
,	I-OutcomeDefinition
normalisation	I-OutcomeDefinition
of	I-OutcomeDefinition
SpO2	I-OutcomeDefinition
(	I-OutcomeDefinition
>	I-OutcomeDefinition
94	I-OutcomeDefinition
%	I-OutcomeDefinition
on	I-OutcomeDefinition
room	I-OutcomeDefinition
air	I-OutcomeDefinition
)	I-OutcomeDefinition
,	I-OutcomeDefinition
and	I-OutcomeDefinition
disappearance	I-OutcomeDefinition
of	I-OutcomeDefinition
respiratory	I-OutcomeDefinition
symptoms	I-OutcomeDefinition
including	I-OutcomeDefinition
nasal	I-OutcomeDefinition
congestion	I-OutcomeDefinition
,	I-OutcomeDefinition
cough	I-OutcomeDefinition
,	I-OutcomeDefinition
sore	I-OutcomeDefinition
throat	I-OutcomeDefinition
,	I-OutcomeDefinition
sputum	I-OutcomeDefinition
production	I-OutcomeDefinition
,	I-OutcomeDefinition
and	I-OutcomeDefinition
shortness	I-OutcomeDefinition
of	I-OutcomeDefinition
breath	I-OutcomeDefinition
.	O

